Colgate-Palmolive
Makes Colgate oral care, Palmolive household products and Hill's specialty pet nutrition.
Something off on this page? Send us feedback.
Profile
Sells toothpaste, toothbrushes, soap, deodorant, household cleaners, skin care and Hill's specialty pet food through retailers, distributors, veterinarians and e-commerce channels worldwide. Most revenue comes from outside the United States, and consumer products are managed by geography while pet nutrition is reported separately.
Builds a global consumer-products portfolio around Oral, Personal and Home Care and Hill's Pet Nutrition. Colgate toothpastes, toothbrushes and mouthwashes anchor oral care; Palmolive, Softsoap and Irish Spring span soaps and body care, while Ajax and Fabuloso cover household cleaning. EltaMD, Filorga and PCA SKIN add skin health.
Hill's sells everyday and therapeutic dog-and-cat nutrition under Science Diet and Prescription Diet through pet retailers, veterinarians and e-commerce channels. Prime100 adds fresh pet food in Australia. Science-led product development, advertising and broad retail distribution support category penetration across developed and emerging markets.
Most sales come from outside the United States. Consumer products are managed through four geographic divisions, while Hill's is reported separately; exposure includes foreign-currency swings, retailer bargaining power, commodity costs and global product regulations.
Company facts
Key statistics
Year to date +16.8% · Average volume (30d) 4.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | RBC Capital | Reiterate | Outperform | $102 | $104 | |
| Aug 3, 2026 | Deutsche Bank | Reiterate | Buy | $99 | $101 | |
| Aug 3, 2026 | Morgan Stanley | Reiterate | Overweight | $100 | $104 | |
| Aug 3, 2026 | UBS | Reiterate | Buy | $100 | $109 | |
| Jul 8, 2026 | Wells Fargo | Reiterate | Equal Weight | $92 | $95 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026Q2 FY26 | $0.95 | $0.99 | +4.5% | $5.36B | $5.36B | +0.1% | −0.33% |
| May 1, 2026Q1 FY26 | $0.94 | $0.97 | +2.9% | $5.22B | $5.32B | +2.1% | −2.17% |
| Jan 30, 2026Q4 FY25 | $0.91 | $0.95 | +4.2% | $5.12B | $5.23B | +2.1% | +1.77% |
| Oct 31, 2025Q3 FY25 | $0.89 | $0.91 | +2.4% | $5.13B | $5.13B | +0.1% | −2.69% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.91B | $5.11B | $5.13B | $5.23B | $5.32B | $5.36B | |
| Gross profit | $2.99B | $3.07B | $3.05B | $3.15B | $3.23B | $3.30B | |
| Operating income | $1.08B | $1.08B | $1.10B | $1.08B | $1.16B | $1.02B | |
| Net income | $690.0M | $743.0M | $735.0M | −$37.0M | $646.0M | $693.0M | |
| Diluted EPS | $0.85 | $0.91 | $0.91 | −$0.05 | $0.80 | $0.86 | |
| Gross margin | 60.8% | 60.1% | 59.4% | 60.2% | 60.6% | 61.5% | |
| Operating margin | 21.9% | 21.1% | 21.4% | 20.6% | 21.7% | 19.0% |
Fiscal years (4-quarter sums)FY21 $17.42B · FY22 $17.97B · FY23 $19.46B · FY24 $20.10B · FY25 $20.38B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.37B · Total debt $7.86B · Total assets $16.79B · Shareholders' equity $236.0M
Dividends
Raised for 51 straight years — most recently to $0.53 from $0.52 in Apr 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 20, 2026 | Jul 20 | Aug 14 | $0.53 | |
| Apr 20, 2026 | Apr 20 | May 15 | $0.53 | raised from $0.52 |
| Jan 21, 2026 | Jan 21 | Feb 13 | $0.52 | |
| Oct 17, 2025 | Oct 17 | Nov 14 | $0.52 | |
| Jul 18, 2025 | Jul 18 | Aug 15 | $0.52 | |
| Apr 17, 2025 | Apr 17 | May 15 | $0.52 | raised from $0.50 |
| Jan 21, 2025 | Jan 21 | Feb 14 | $0.50 | |
| Oct 18, 2024 | Oct 18 | Nov 15 | $0.50 |
Ownership
Shares outstanding 800.19M · Float 747.88M · 93.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 69.92M | 8.74% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 52.25M | 6.53% | 13F | Aug 13, 2026 |
| State Street Corp | 47.02M | 5.88% | 13F | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 27.91M | 3.49% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 24.02M | 3.00% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Panagiotis Tsourapas | officer: COO, CD, EMEA, APac, Skin | −10,000 | $92.05 |
| Aug 6, 2026 | John T. Cahill | director | −4,170 | $93.37 |
| Aug 5, 2026 | Noel R. Wallace | director, officer: Chairman, President & CEO | −161,021 | $92.52 |
| Aug 4, 2026 | Noel R. Wallace | director, officer: Chairman, President & CEO | −161,021 | $91.92 |
| May 15, 2026 | Gregory Malcolm | officer: EVP and Controller | −2,300 | $88.44 |
Peers
- Procter & Gamble
Head-to-head rival across oral care, personal care, and home care worldwide.
- Unilever (ADR)
Oral, personal, and home care rival with dominant emerging-market share.
- Haleon (ADR)
Dominant in therapeutic oral care — sensitivity, gum health, and denture care.
- Church & Dwight
Oral care and personal care challenger via Arm & Hammer and TheraBreath.
- Kenvue
Mouthwash rival via Listerine; skin health overlap via Neutrogena and Aveeno.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Colgate-Palmolive | $90.85 | +0.15% | $72.62B | 36.0 | 23.1 | 3.5 | +4.9% |
| Procter & Gamble | $143.75 | +0.01% | $341.75B | 21.7 | 20.5 | 3.9 | +1.5% |
| Unilever (ADR) | $63.77 | −2.01% | $140.18B | 21.7 | — | 2.6 | −17.9% |
| Haleon (ADR) | $10.11 | +0.05% | $44.52B | 20.7 | 10.8 | 2.9 | +3.7% |
| Church & Dwight | $101.26 | +0.03% | $23.99B | 32.7 | 25.9 | 3.9 | +1.6% |
| Kenvue | $19.17 | +0.03% | $36.81B | 22.0 | 16.0 | 2.4 | +3.0% |
| Median | 21.7 | 18.3 | 2.9 | +1.6% |